NorgesInvestor is an asset management group based in Oslo, Norway, with offices in Stockholm. The firm focuses on strategic and financial value creation through private equity investments, discretionary wealth management, investments in listed securities, and private equity secondaries. Founded in 1996, it serves clients in Norway and Sweden and targets sectors including telecommunications, information technology, retail, alternative energy, oil services, manufacturing, and technology. The organization operates as an independent, financially solid firm that provides wealth management and equity management services alongside asset management.
Algeta ASA is an oncology company headquartered in Oslo, Norway, that specializes in developing targeted therapies for cancer treatment using its proprietary alpha-pharmaceutical platform. Founded in 1997, the company focuses on fulfilling unmet medical needs in cancer care. Its lead product, radium-223 dichloride, has successfully completed Phase III clinical trials for treating castration-resistant prostate cancer with bone metastases. Additionally, Algeta is advancing its research on thorium-227, an alpha-emitter that is in the preclinical phase and is being developed in conjunction with tumor-targeting molecules to create targeted thorium conjugates. The company has a collaboration agreement with Bayer Pharma AG for the global development and commercialization of radium-223. Algeta was previously known as Anticancer Therapeutic Inventions AS before rebranding in 2003.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.